RINVOQ (upadacitinib) is a Janus Kinase inhibitor that is currently approved to treat a variety of conditions: moderate to severe atopic dermatitis, active psoriatis arthritis, moderate to severe rheumatoid arthritis,…
In early March 2024, Tyler Patchen reported that the U.S. Food and Drug Administration (FDA) approved both intravenous and subcutaneous formulations of Tyenne (tocilizumab-aazg) for use in a variety of…
According to a story from Healio, recent research has suggested that giant cell arteritis, a rare immune-mediated disease, could be made worse from the use of checkpoint inhibitors, a class…
Clinical trials can be beneficial in many ways. For one, these trials show researchers whether a treatment’s impact is durable and sustained. Determining this often requires some follow-up period. According…
According to Healio, giant-cell arteritis (GCA) is seeing a worrying trend. Over a period of 18 years (2000-2018), mortality rates for GCA increased from 50 to 57.6 per 1,000 deaths.…
According to a story from Healio, new guidelines for the treatment of different forms of vasculitis recommend the use of biologic therapies as a first-line option for certain patients. It…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
